GC Wealth Management RIA LLC Acquires New Shares in Vera Therapeutics, Inc. $VERA

GC Wealth Management RIA LLC acquired a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 13,567 shares of the company’s stock, valued at approximately $320,000.

Other institutional investors also recently added to or reduced their stakes in the company. Quarry LP boosted its position in Vera Therapeutics by 25.0% during the 1st quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $60,000 after acquiring an additional 500 shares during the period. AlphaQuest LLC boosted its position in Vera Therapeutics by 404.7% during the 1st quarter. AlphaQuest LLC now owns 4,007 shares of the company’s stock worth $96,000 after acquiring an additional 3,213 shares during the period. Fifth Third Bancorp acquired a new position in Vera Therapeutics during the 2nd quarter worth $102,000. GAMMA Investing LLC boosted its position in Vera Therapeutics by 1,779.1% during the 1st quarter. GAMMA Investing LLC now owns 8,287 shares of the company’s stock worth $199,000 after acquiring an additional 7,846 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Vera Therapeutics by 19.7% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,533 shares of the company’s stock worth $229,000 after acquiring an additional 1,572 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a research report on Thursday, September 18th. JPMorgan Chase & Co. reduced their price target on Vera Therapeutics from $56.00 to $53.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Finally, Wolfe Research reiterated a “peer perform” rating on shares of Vera Therapeutics in a research report on Monday, August 4th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Vera Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $63.00.

Vera Therapeutics Trading Down 0.9%

Shares of Vera Therapeutics stock opened at $28.79 on Thursday. The company has a quick ratio of 17.03, a current ratio of 17.03 and a debt-to-equity ratio of 0.16. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of -8.04 and a beta of 1.23. The business has a fifty day simple moving average of $23.13 and a 200-day simple moving average of $23.08. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same quarter last year, the business posted ($0.62) earnings per share. On average, equities analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.